PRESS RELEASES

All Releases
Jul 26, 2018
AUSTIN, Texas , July 26, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today reported financial results for the second quarter ended June 30 , 2018.  Net loss was $2.5 million , or $0.36 per share.  This compared to a net loss of $4.2 million , or $0.64
Jun 26, 2018
AUSTIN, Texas , June 26, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.
May 09, 2018
– June 26 th Advisory Committee Meeting for REMOXY ER –  – August 7 th PDUFA Target Date for REMOXY ER – AUSTIN, Texas , May 09, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today reported financial results for the first quarter ended March 31 , 2018. 
Mar 19, 2018
AUSTIN, Texas , March 19, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, announced today that the U.S. Food and Drug Administration ( FDA ) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended-release
Mar 01, 2018
AUSTIN, Texas , March 01, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S. Food and Drug Administration ( FDA ) has determined that a New Drug Application (NDA) for REMOXY ER, the Company’s lead drug candidate, is sufficiently complete to permit a
Feb 13, 2018
AUSTIN, Texas , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the resubmission to the U.S. Food and Drug Administration ( FDA ) of a New Drug Application (NDA) for REMOXY ® ER, its lead drug candidate.  The Company expects a six-month review cycle by FDA .
Feb 05, 2018
– 2018 Focus will be on REMOXY, Fiscal Discipline and Advancing Pipeline – AUSTIN, Texas , Feb. 05, 2018 (GLOBE NEWSWIRE) --   Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the year ended December 31 , 2017.  Net loss in 2017 was $11.9 million , or $1.82 per share,
Jan 09, 2018
- Study Meets Primary Endpoint (p - - REMOXY NDA Remains On-Track for Resubmission in Q1 2018 - AUSTIN, Texas, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced positive results from a human abuse potential study of its late-stage drug candidate, REMOXY.  Study